Literature DB >> 7137253

Comparison of antepartum testing schemes for the management of the postdate pregnancy.

R D Eden, R Z Gergely, B S Schifrin, M E Wade.   

Abstract

We analyzed the outcome results of 583 postdate pregnancies managed prospectively by one of three antepartum testing schemes, each predicated on the nonstress test. In scheme 1, we relied upon the contraction stress test for evaluation of the nonreactive nonstress test. In scheme 2, we used a modified biophysical profile to evaluate the nonreactive nonstress test. In addition, patients were tested semiweekly. In scheme 3, we added routine weekly ultrasound evaluation of amniotic fluid volume to scheme 2. Only in scheme 3 did we induce labor for decreased amniotic fluid volume or fetal cardiac decelerations irrespective of reactivity. The incidence of fetal distress, perinatal mortality, and perinatal morbidity was increased in babies with decelerations or decreased amniotic fluid volume. Nevertheless, outcome results in scheme 2 were improved over those with scheme 1 and were best with scheme 3. These results suggest a benefit to both semiweekly testing and liberalized criteria for intervention in postdate pregnancies. We also compared the outcome results of scheme 3 with those reported for schemes in which the weekly contraction stress test was used as the primary form of surveillance. We found the outcome results comparable in that both schemes showed minimal mortality and morbidity statistics but high intervention rates (25% to 30%). Differences in methodology and test criteria, however, make such comparisons less than ideal.

Entities:  

Mesh:

Year:  1982        PMID: 7137253     DOI: 10.1016/0002-9378(82)90438-0

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

1.  Randomised trial of outpatient induction of labor with vaginal PGE2 at 40-41 weeks of gestation versus expectant management.

Authors:  G Ohel; D Rahav; H Rothbart; M Ruach
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.